Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
Eurobio Scientific→CareDx Lab Products division
Apr 16, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Garda Therapeutics has entered into an agreement to acquire Assertio Holdings through a cash tender offer followed by a merger. The offer provides for $18.00 per share in cash as the base purchase price.
The tender offer price also includes one contingent value right per share under a CVR agreement, with potential additional cash payments tied to the CVR terms. After the offer, the purchaser will merge with and into Assertio, with Assertio surviving as a wholly owned subsidiary of Garda. The filing is an Amendment No. 1 to a Form 8-K dated April 8, 2026, correcting and replacing Item 1.01 and updating conformed signatures on certain exhibits.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Eurobio Scientific→CareDx Lab Products division
Apr 16, 2026
Quvara Medical→Becton Dickinson
Apr 15, 2026
Parkview Health→Witham Health Services
Apr 15, 2026
Surgery Partners→Preferred Vascular Group
Apr 15, 2026
Sectra→Oxipit
Apr 15, 2026